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Introduction. Anti-MRSA agents may be eliminated during continuous hemodiafiltration (CHDF), 
not only by diffusion and ultrafiltration but also by adsorption onto hemofilters, which may be 
affected by the binding of agents to albumin. The present study was aimed to investigate the affinity 
of anti-MRSA agents to hemofilters and pharmacokinetic properties of teicoplanin during CHDF. 
Methods. As a screening experiment, linezolid, teicoplanin and vancomycin were dissolved in 
Krebs-Ringer’s bicarbonate solution and shaked in a flask with 3 kinds of filter membrane piece; 
polysulfone (PS), polyacrylonitrile (PAN), and polymethylmethacrylate (PMMA).  The in vitro 
model of continuous hemodiafiltration consists of a 1 L beaker containing Krebs-Ringer’s bicarbonate 
solution with or without human albumin (albumin concentration: 0, 3 g/dL) as an artificial plasma.  
The solution containing teicoplanin at an initial concentration of 50 μg/mL was circulated at a flow 
rate of 100 mL/min through three kinds of hemofilters. The flow rates of dialysate and ultrafiltrate 
were 500 mL/h, respectively.  Teicoplanin concentrations of “plasma” and ultrafiltrate were 
determined by HPLC. 
Results.  In the screening experiment, teicoplanin was predominantly adosorbed onto PS and 
PMMA membranes.  Teicoplanin was eliminated mainly by adsorption during continuous 
hemodiafiltration using PS and PMMA hemofilters.  The PS and PMMA eliminated teicoplanin 
more rapidly than PAN.  The presence of albumin had a significant but small influence. 
Conclusions. We should adjust the dosing of teicoplanin by close monitoring during CHDF using PS 
or PMMA.  Present recommendations of teicoplanin dosing should be re-evaluated in patients on 
CHDF by a future clinical study. 
 





Anti-methicillin-resistant Staphylococcus aureus (MRSA) agents are frequently administered for the 
treatment of severe infections or sepsis caused by MRSA in critically ill patients who are often 
complicated with acute renal dysfunction.  Hemodiafiltration (HDF) is widely applied to critically ill 
patients with acute kidney and other organ dysfunctions.  Continuous hemodiafiltration (CHDF) 
has a minor influence on the hemodynamics and thus may be used in critically ill patients with 
unstable hemodynamics in the intensive care unit.  In patients receiving HDF or CHDF, the optimal 
dose of antimicrobiotics including anti-MRSA agents should be determined by considering the renal 
function of patients as well as by estimating the clearance by the filter membrane [1,2].  
Additionally, anti-MRSA agents have different affinities to plasma albumin.  For instance, 
teicoplanin is bound to plasma albumin at the highest rate (90%) [3].  It has been assumed that free 
drugs unbound to albumin are eliminated by diffusion or ultrafiltration in HDF [4,5].   
Evidence has been accumulating that some drugs including anti-MRSA agents may be eliminated 
during HDF or CHDF not only by diffusion and ultrafiltration but also by adsorption onto filter 
membranes [6-8].  The issue of antibiotic adsorption to haemofilters is a largely neglected but 
important area of research. Some drugs and albumin has been reported to interact with filter 
membranes [9]. 
Taken together, the influence of HDF or CHDF on pharmacokinetics of anti-MRSA drugs are 
suspected to depend partially on filter membrane and plasma albumin.  In the present study, we 
first compared the affinity of anti-MRSA agents to various filter membrane in a simple screening 
experiment.  Then, we investigated the effects of filter material and plasma albumin on teicoplanin 
elimination by adsorption onto filter membranes in an in vitro CHDF circuit model, since there are 
considerable technical and ethical problems which make the measurement of adsorption difficult in a 
clinical setting or in vivo.  
 
Materials and Methods 
Screening for anti-MRSA agent with high affinity to filter membrane 
 
We firstly compared the affinity of anti-MRSA agents to three kinds of hemofilters, i.e. 
polyacrylonitrile (PAN) (APF-06S, Asahi Kasei Kuraray Medical, Japan), polysulfone (PS) (AEF-07, 
Asahi Kasei Kuraray Medical, Japan) and polymethylmethacrylate (PMMA) (CH-0.6N, Toray 
Medical, Japan).  We applied linezolid, teicoplanin or vancomycin as an anti-MRSA agent.  As 
shown in Figure 1, the anti-MRSA agents were dissolved in 50 ml of Krebs-Ringer-Bicarbonate 
(KRB) solution in Erlenmeyer flask.  The pH of KRB solution was adjusted at 7.4 and maintained 
with 5% carbon dioxide gas mixture.  The concentration of each anti-MRSA agent was set to 20 μ
g/ml for linezolid, 50 μg/ml for teicoplanin and 50 μg/ml for vancomycin, respectively.  The filter 
membranes were first primed with KRB at a transmenbrane pressure to obtain a sufficient filtration 
fluid, and then were cut into 5 mm pieces.  The pieces were added to the solution.  The flask was 
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incubated for 60 min in a 37ºC water bath.  Then the concentrations of each anti-MRSA agent before 
and after the incubation were determined by the high-performance liquid chromatography (HPLC) 
system (described in detail in other section).  Then adsorption rate of each drug was calculated 







Where C0 is the concentration of the drug at 0 min and C60 is the concentration of the drug at 60 min. 
The anti-MRSA agent solutions represented 1/240 of total extracellular fluid (12 litters) and 
hemofilter surface area clinically used (0.6 m2 or 0.7 m2). 
 
 
In vitro CHDF circulation experiment for teicoplanin 
 
The in vitro model of CHDF consists of 1 litter beaker containing KRB with or without human 
albumin (Figure. 2).  The CHDF was performed using an ACH-10 system (Asahi Kasei Kuraray 
Medical, Japan).  Albumin concentration was set to 3 g/dl using 25% human serum albumin (CSL 
Behring, Japan).  The KRB containing teicoplanin at an initial concentration of 50 g/ml was 
circulated at a flow rate of 100 ml/min through three filter membranes, i.e. PS, PAN and PMMA and 
the circuits (CHD-400N, Asahi Kasei Kuraray Medical, Japan).  The pH of KRB solution was 
adjusted at 7.4 and continuously equilibrated with a 5% carbon dioxide gas mixture.  We discarded 
200 ml of KRB to wash the circuit.  The flow rates of dialysate, ultrafiltrate and fluid replacement 
were 500 ml/h, respectively.  After teicoplanin was added to the beaker, the system was allowed to 
be primed for 5 min at a flow rate of 100 ml/min.  Following the priming, dialysis and ultrafiltration 
was started (time point 0 min). 
The KRB samples for assay were taken at the inlet and outlet of the hemofilter simultaneously with 
filtrate samples at time points of 0, 15, 30, 45, 60, 90 and 120 min.  Additionally, KRB samples were 
taken before the priming (baseline, BL) and total filtrate samples at time point 120 min.  These 
samples were stored at -80ºC and the concentrations of teicoplanin were determined by HPLC 










Where CBL is the concentration of teicoplanin at BL, C200 ml is the concentration of teicoplanin in 
discarded 200 ml KRB, CF Total is the concentration of teicoplanin in total filtrate at 120 min, VF Total is 
the volume of total filtrate at 120 min, C120 is the concentration of teicoplanin at the inlet of the filter 
membranes, and V is the total volume of KRB. 
The CHDF clearance which represents elimination by adsorption as well as diffusion and 
ultrafiltration was calculated by following equation: 
    de Vk ＝CHDFCL  
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Where ke is elimination rate constant and Vd is the distribution volume of teicoplanin, ie., the 
volume of KRB used in this system (= 1 litter). The ke was estimated from the initial slope of the 
concentration versus time curve in semi-logarithmic plot.  
 
 
Simple circulation without filtration or dialysis for teicoplanin 
 
To confirm the absorption of teicoplanin onto membrane filters and eliminate the effect of dialysis 
and filtration, we performed simple circulation experiment.  The simple circulation model consists 
of 1 litter beaker containing KRB without human albumin.  The KRB containing teicoplanin at an 
initial concentration of 50 g/ml was circulated at a flow rate of 100 ml/min without filtration and 
dialysis through the three filter membranes. 
The KRB samples for assay were taken at the inlet and outlet of the filter membranes 
simultaneously at time points of 0, 15, 30, 45, 60, 90 and 120 min.  Additionally, KRB samples were 
taken before equilibration.  These samples were stored at -80ºC and the concentrations of 
teicoplanin were determined by HPLC system later.  To evaluate the extent of teicoplanin 
absorption onto circuit, we performed similar experiment without filter membrane.  In the sham 
group without filter membranes, KRB containing teicoplanin was circulated through the CHDF 
circuit excluding the filter membranes. 
 
 
Determination of anti-MRSA agents using HPLC 
 
The concentrations of anti-MRSA agents were determined using HPLC method.  This system was 
composed of LC-10AD pump (Shimadzu, Japan), Shim-pack CLC-ODS (C18, 150 × 6.0 mm) column 
(Shimadzu, Japan), SIL-10A auto injector (Shimadzu, Japan), CTO-10AC column oven (Shimadzu, 
Japan), SPD-6A UV spectrometric detector (Shimadzu, Japan) and C-R8A chromatopac integrator 
(Shimadzu, Japan). 
The concentration of linezolid was determined by a modified HPLC technique [10].  Briefly, during 
the mobile phase, a mixture of acetonitrile and 50 mM sodium acetate buffer adjust to pH 4.0 (25:75, 
v/v) was pumped at a rate of 1.0 ml/min.  The UV absorbance of eluent was monitored at 253 nm.  
The temperature of the column was maintained at 40ºC.  Sample treatment involved vortex-mixing 
of 100 L samples with 200 ml acetonitrile containing 50 g/ml mephenesin (internal standard, IS) 
in a 1.5 ml centrifuge tube and centrifugation at 10,000 g for 5 min (4ºC).  Two hundred l aliquot of 
the supernatant liquid was transferred into a HPLC auto injector vial for injection of 20 l onto the 
column.  
The concentration of teicoplanin was measured by HPLC with slight modifications to method 
previously described [11].  The mobile phase consisted of acetonitrile / 50 mM sodium dihydrogen 
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phosphate aqueous solution (28:72, v/v) pumped at a rate of 1.5 ml. Teicoplanin was detected at a 
wavelength of 218 nm.  The temperature of the column was maintained at 40ºC.  Two hundred l of 
distilled water and 50 L of 50 g/ml 5-(4-hydroxyphenyl)-5-phenylhydantoin (IS) methanol solution 
were added to 50 l of samples, and then 400 l of acetonitrile was added to precipitate proteins.  
After centrifugation (5 min, 10,000 g, 4 ºC), 600 l of the supernatant was transferred to another 
centrifuge tube and 10 l of 2 M HCl and 400 l of chloroform were added, and then vortexed and 
centrifuged (5 min, 10,000 g, 4 ºC).  Fifty l of the obtained aqueous layer was injected into the 
HPLC system described above. 
The concentratin of vancomycin was determined by HPLC with a modified method of Luksa J et al. 
[11].  The mobile phase was prepared by premixing acetonitrile and 50 mM sodium dihydrogen 
phosphate buffer (pH 2.5) in a 10:90 (v/v) ratio, and pumped through the column at a flow rate of 1 
ml/min.  Separated components were detected at 230 nm and the temperature of the column was 
maintained at 40ºC.  Two hundred l of samples were mixed with 50 l of 20 g/ml caffeine (IS) 
aqueous solution and 10 l of 60% perchloric acid.  The mixture was vortexed and then added with 
10 l of 6 M KCL .  After centrifugation (5 min, 10,000 g, 4 ºC), 200 l of the supernatant was 
transferred to another centrifuge tube and added with 400 l of diethyl, and then vortexed and 
centrifuged (5 min, 10,000 g, 4 ºC).  One hundred l aliquot of the aqueous layer was transferred 





Data are expressed as mean ± SE.  One-way or two-way Analysis of variance (ANOVA) was applied 
for non-repeated measurement.  Repeated measures ANOVA followed by Tukey-Kramer test were 
applied for repeated or serial determinations.  Statistical significance was reached when p<0.05.  




Screening for anti-MRSA agent with high affinity to filter membrane 
 
Fig. 3 represents the adsorption rate of anti-MRSA agents onto the three different filter membranes 
in the screening experiment.  When compared with the absorption rate of each drug to the blank 
applying no filter membrane, teicoplanin was adsorbed significantly by PS and PMMA membranes.  
Linezolid and vancomycin were not absorbed by any filter membrane.  Therefore, we focused on 





In vitro CHDF experiment using teicoplanin with or without albumin 
 
To confirm the absorption of teicoplanin onto the filter membrane under the condition of CHDF, in 
vitro CHDF experiment using teicoplanin was performed.  Furthermore, to examine the effects of 
albumin on absorption of teicoplanin to filter membrane, we conducted in vitro CHDF experiment 
with or without albumin.  Fig. 4 shows the time course of teicoplanin concentration throughout in 
vitro CHDF experiment with albumin.  In the both experiments with and without albumin, the 
concentration of teicoplanin was consecutively decreased in any filter membrane and the decrease in 
teicoplanin concentration was significantly different among the three filter membranes.  The extent 
of the decline was largest in PMMA and smallest in PAN membrane (Two-way repeated measures 
ANOVA followed by Tukey-Kramer test, p < 0.05). 
PK parameters were summarized in Table 1.  When the data were analyzed by two-way ANOVA, 
the CHDF clearance (CLCHDF) was significantly affected by filter membrane (p < 0.01) and albumin 
(p < 0.01).  There was a significant interaction of filter membrane and albumin (p < 0.01).  The 
CLCHDF was largest in PMMA membrane in the absence of albumin and was smallest in PAN 
membranes (Tukey-Kramer test, p < 0.01).  Addition of albumin into KRB significantly decreased 
the CLCHDF for all the filter membranes (Tukey-Kramer test, p < 0.05). 
As shown in Table1, the adsorption rate of teicoplanin on to each filter membrane with or without 
albumin in in vitro CHDF experiment.  Independent of the existence of albumin, the absorption 
rates of teicoplanin were significantly high in PS and PMMA filter membrane as compared with PAN 
membrane.  The PMMA membrane has the highest binding capacity to teicoplanin, while PAN 
membrane has a negligible binding capacity.  Addition of albumin into KRB slightly but 
significantly decreased the adsorption rate of teicoplanin onto PS and PMMA membranes 
(Tukey-Kramer test, p < 0.05).  The adsorption rate of teicoplanin was significantly influenced by 
filter membrane (p < 0.01) and albumin (p < 0.01), indicating a significant interaction of filter 
membrane and albumin (p < 0.01). 
 
 
Simple circulating model without filtration or dialysis 
 
To confirm the absorption of teicoplanin onto membrane filters and eliminate the effect of dialysis 
and filtration, we performed simple circulation experiment.  Moreover, to evaluate the extent of 
teicoplanin absorption onto circuit, the same experiment without filter membrane was conducted as 
a control group.  Fig. 5 shows the time course of the teicoplanin concentration during a simple 
circulation.  In control experiment, the concentration of teicoplanin was maintained throughout the 
experiment, indicating that the adsorption of teicoplanin to circuit is little.  Compared with the 
control experiment, circulation through three filter membrane significantly decreased teicoplanin 
concentration (repeated measures ANOVA followed by Tukey-Kramer test, P < 0.01).  The extent of 
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the decrease is largest in PMMA and smallest in PAN.  The adsorption of teicoplanin onto filter 




In the present study, we first screened for anti-MRSA agent with high affinity to filter membrane in 
a shaken flask containing pieces of filter membrane and KRB solution. Since the absorption may 
occur within the wall or pores of the membrane as well as on the surface, we carefully primed the 
entire filters with KRB before cutting them into pieces.  Teicoplanin was significantly and 
predominantly adsorbed by PS and PMMA membranes.  Either linezolid or vancomycin was not 
significantly absorbed by any filter membrane.  Recent studies have shown that vancomycin is 
adsorbed to hemodialysis membrane [25,26] .  The discrepancy between these reports and ours may 
be explained by the differences in experiment method. Our screening model was very simple and 
excluded the effect of perfusion and transmenbrane pressures on the adsorption of anti-MRSA 
agents. 
Since teicoplanin has the highest affinity to filter material, we investigated the influence of filter 
membrane and plasma albumin on teicoplanin elimination by adsorption onto filter membrane.  
The major finding of our study is that teicoplanin is significantly adsorbed by PS and PMMA filter 
membranes but not by PAN membrane.  This property of teicoplanin was confirmed by 3 series of 
experiment as follows.  Firstly, in the screening experiment, teicoplanin was a unique anti-MRSA 
agent binding to PMMA and PS membranes.  Secondly, in the in vitro CHDF experiment, we 
demonstrated that high affinity of teicoplanin to PS and PMMA membranes may attribute to a large 
CLCHDF when teicoplanin is administered during CHDF using PS and PMMA membrane.  Finally, in 
a circulating model without filtration and dialysis, we showed that simple circulation through 
PMMA and PS membranes causes a significant and sufficient decrease in teicoplanin concentration.  
Since teicoplanin binds to plasma albumin at a rate of 90% [2], we investigated the effect of albumin 
on the PK parameters of teicoplanin in the in vitro CHDF experiment.  When albumin was added to 
KRB solution, the CLCHDF was greatly reduced in all the membrane tested.  However, the addition 
of albumin exerted a significant but small effect on the adsorption rate.  It has been shown that 
drugs with a high binding rate to albumin are eliminated defectively by diffusion and ultrafiltration 
[4, 5].  It is suggested that albumin attenuates the teicoplanin elimination mainly by affecting the 
diffusion and ultrafiltration through the membranes.  A similar observation has been reported by 
Oborne et. al. that the presence of albumin decreases the amount of fluconazole adsorbed by PS and 
polyamide membranes [9].  
In accordance to the results of present study, Menth et al. reported that teicoplanin may be 
eliminated by adsorption to several dialysis membranes, including PAN, PS and PMMA [13].  
Clinical evidence has been accumulated that elimination of teicoplanin by hemodialysis and / or 
hemofiltration may be dependent on the applied membrane [2,6, 14-17].  The therapeutic drug 
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monitoring-guided dosage of teicoplanin is required for the patients treated with blood purification 
[14].  Considering the results of present study, it is necessary to adjust the dosage and the timing of 
teicoplanin administration during CHDF using PS or PMMA membrane.  It may be considered that 
PAN instead of PS or PMMA should be selected as a filter membrane when teicoplanin 
administration is needed during CHDF.  A high affinity to some filter membranes has been reported 
for other antibiotics [7-9, 18-20]. 
One of the proposed mechanisms by which some drugs bind to filter membranes is the electrostatic 
coupling of membranes and drugs that depends on the electric charges of membranes and drugs.  
Teicoplanin has carboxyl and amino terminals with pKs of 3.1 and 7.1, respectively.  It is charged 
negatively at a physiological pH of 7.4.  PS membrane has no net charge, while PMMA and PAN 
membranes have a negative charge [21, 22].  Therefore, the electrostatic coupling may not explain 
whether teicoplanin is predominantly adsorbed by PMMA and PS membranes.  Teicoplanin is a  
glycopeptide whose structure resembles to that of protein.  Since various proteins and polypeptides 
including 2-microglobulin [23] and cytokines [24] binds to PMMA membrane, a non-specific 
mechanism may be involved in the binding of teicoplanin to PMMA membrane. 
Limitations 
Since the present study was conducted using in vitro model, the results of present study should be 
clinically confirmed. Critically ill patients receive various drugs and the concentrations of many 
biologically active substances are elevated in their plasma. teicoplanin and those substances may 
interact with albumin and filter membrane.  We set the initial concentration of teicoplanin at 50 μ
g/mL, considering a Cmax value obtained by a common clinical dosage.  The Cmax of teicoplanin 
may be higher when loading dose is applied.  A higher concentration of teicoplanin may affect the 
adsorption rate.  Furthermore, the parameters of CHDF including QF may vary among institutes 
and countries.  These parameters may also influence the adsorption rate.  
Our data suggests a clinical study is needed to re-evaluate current recommendations 
 
Conclusions 
Teicoplanin was eliminated mainly by adsorption during CHDF using PS and PMMA hemofilters.  
The PS and PMMA eliminated teicoplanin more rapidly than PAN.  The presence of albumin had a 
significant but small influence.  It may be necessary to adjust the dosage and the timing of 
teicoplanin administration by a close monitoring of drug concentration during CHDF using PS or 
PMMA membrane.  A large clinical study is needed to confirm our in vitro observations and present 
recommendations of teicoplanin dosing should be re-evaluated in patients on CHDF. 
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  (mL/min) (%) (mL/min) (%) 
PAN 12.6 ± 0.6 0.4 ± 0.2  6.7 ± 0.5 3.7 ± 1.3 
PS 50.6 ± 1.5 69.8 ± 0.5  27.8± 0.4 61.4 ± 2.8 
PMMA 60.8 ± 2.7 89.4 ± 1.4  26.7 ± 0.6 75.6 ± 1.1 
 
Each value represents the mean ± S.E. (n = 3).  The CHDF clearance (CLCHDF) and adsorption was 
estimated as described in the “Materials and Methods”. CLCHDF was significantly affected by filter 
membrane and albumin (p < 0.01, two-way ANOVA).  There was a significant interaction of filter 
membrane and albumin (p < 0.01, two-way ANOVA). The adsorption rate of TEIC was significantly 
different among the three filter membranes (PMMA > PS > PAN, two-way ANOVA followed by 









Figure 1:  Device used in the screening experiment. 
 
 






Figure 3:  Adsorption rate of anti-MRSA agents onto three filter membrane in screening experiment.  
Adsorption rate was calculated at the end of experiment (60 min).  Each column with vertical bar 
represents the means ± S.E. (n = 6).  ** significantly different from the blank (one-way ANOVA 






Figure 4:  Changes in teicoplanin concentration at the inlet of filter membranes during in vitro 
CHDF experiment with albumin.  Each symbol with vertical bar represents the mean ± S.E. (n = 3).  
In the two series of experiments with (shown in this figure)and without albumin (not shown), the 
decline of teicoplanin was significantly different among the three filter membranes (PMMA > PS > 






Figure 5:  Changes in teicoplanin concentration at the inlet of filter membranes during a simple 
circulation without filtration or dialysis.  Each symbol with vertical bar represents the mean ± S.E. 
(n = 3).  The decline of teicoplanin was significantly different among the control and the three 
membranes. (two-way repeated measures ANOVA followed by Tukey-Kramer test, p < 0.05). 
 
 
 
 
 
 
